Could a single blood thinner after stents be safer?
NCT ID NCT06916520
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a reduced dose of the blood thinner prasugrel (5 mg), taken alone without aspirin, is safe and effective for patients who have had a stent placed for heart disease. Researchers will compare this approach to standard dual antiplatelet therapy (aspirin plus another blood thinner). The goal is to see if the single-drug strategy reduces bleeding complications while still preventing heart attacks, strokes, and other serious events. The trial plans to enroll 300 patients and follow them for 6 to 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Prasugrel 5 mg
What this could lead to
If successful, this could show that a lower dose of prasugrel alone is a safe and effective option after stent placement, reducing bleeding risk while still preventing heart attacks and strokes.
What could go wrong
This is a small, single-center Phase 4 trial, so results may not apply to all patients. The lower dose might not prevent clotting events as well as standard dual therapy, and bleeding risks remain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERIAL DISEASE (CAD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam UMC
RECRUITINGAmsterdam, Netherlands
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact